This Article is From May 11, 2023

Drugs Regulator Says Will Prioritise Making Regulation System Simpler

The DCGI is the apex authority in the country responsible for approval of licences of specified categories of drugs such as blood and blood products, intravenous fluids, vaccine and serum.

Advertisement
India News

Rajeev Raghuvanshi said bringing down regulatory intervention in the system is a top priority. (File)

Hyderabad:

Drugs Controller General of India (DCGI) Rajeev Singh Raghuvanshi on Thursday said bringing down regulatory intervention in the system and making it simpler is a top priority for the organisation.

The DCGI is the apex authority in the country responsible for approval of licences of specified categories of drugs such as blood and blood products, intravenous fluids, vaccine and serum. It functions under the Directorate General of Health Services (DGHS) of the Ministry of Health.

Delivering a lecture at the CSIR-Indian Institute of Chemical Technology (IICT) in Hyderabad on the occasion of National Technology Day, he said there are currently many licences and interventions present in the system with a scope of making it much more simpler.

"...our (DCGI) current priorities for a couple of years, the first being, (we) want to reduce the regulatory intervention in the system. There are lot of licences and interventions. There is a scope of making it much more simpler. That is one area, where I have to work," he said.

Another priority area is to improve the subject experts committee where organisations like IICT can help in terms of bringing in new experts into the domain, he said.

Advertisement

Mr Raghuvanshi, who was appointed to the top post in February this year, felt that regulation should be made more research centric.

Another priority area is to constantly keep increasing the footprint in digital space, he added.

Advertisement

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Featured Video Of The Day

Rupee Falls To All-Time Low Of 84.37 Against US Dollar

Advertisement